New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:08 EDTAZN, MACK, DB, KERX, BBY, RMTI, ARUN, WB, SHLD, WUBAOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX WUBA ARUN DB SHLD RMTI MACK WB BBY AZN
News For KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 26, 2015
08:06 EDTRMTIRockwell Medical Triferic approved by FDA
Subscribe for More Information
07:51 EDTRMTIRockwell Medical trading halted, news pending
Note that FDA PDUFA date for Rockwell Medical's Triferic was January 24.
06:10 EDTARUNAruba Networks initiated with a Neutral at Citigroup
Subscribe for More Information
January 23, 2015
11:23 EDTRMTIRockwell Medical volatility elevated into PDUFA
Subscribe for More Information
08:56 EDTRMTIFDA PDUFA Date for Rockwell Medical's Triferic is January 24, 2015
08:35 EDTRMTIRockwell Medical a buy ahead of PDUFA tomorrow, says Summer Street
Summer Street says it would be a buyer of Rockwell Medical shares ahead of tomorrow's FDA action date for Triferic. The firm sees an "excellent" chance of approval and believes Rockwell could be well into labeling discussions with the FDA. It has a Buy rating on the stock with a $25 price target.
January 22, 2015
18:28 EDTMACKOn The Fly: After Hours Movers
Subscribe for More Information
17:54 EDTMACKMerrimack Chief Scientific Officer Ulrik Nielsen resigns
Subscribe for More Information
10:35 EDTBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: CZR ACHN NFLX SN NBR TLM CREE BBY LNCO BBRY
January 21, 2015
19:55 EDTKERXKeryx 9.17M share Secondary priced at $12.00
The deal size was raised to 9.17M shares from 7.2M shares. JPMorgan acted as sole book running manager for the offering.
12:30 EDTAZNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
12:12 EDTSHLD, BBYBest Buy, home retailers seen getting biggest bump from Sears demise
Subscribe for More Information
10:47 EDTBBYOptions with decreasing implied volatility
Subscribe for More Information
10:16 EDTAZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
06:15 EDTRMTIRockwell Medical February volatility elevated into PDUFA
Rockwell Medical February call option implied volatility is at 132, March is at 101, May is at 96; compared to its 26-week average of 9- according to Track Data, suggesting large price movement into PDUFA Date for Triferic on January 24.
January 20, 2015
18:30 EDTKERXOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTKERXKeryx files to sell $100M in common stock
J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
12:01 EDTSHLDOverstock.com to appeal patent infringement case
Subscribe for More Information
10:20 EDTBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: RPRX TLM BBY GME CBST NPSP
08:16 EDTMACKMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use